Medically Reviewed
Dr. Jose Rossello, MD, PhD, MHCM
Preventive Medicine & Public Health Specialist
Last Reviewed: February 23, 2026
Table of Contents
Summary of Key Findings
Medicine use in children reflects the evolving landscape of pediatric disease. Nearly 30% of U.S. children now live with at least one chronic condition — up from approximately 26% two decades ago — driven largely by rising rates of ADHD, autism, anxiety, depression, and obesity. These epidemiological shifts are directly mirrored in prescribing patterns: SSRI prescriptions for youth aged 3–17 have more than doubled from 1.5% to 3.6% between 2006 and 2023, stimulants remain the most commonly prescribed psychiatric medication at 5.3% of all youth, and obesity medication prescriptions for adolescents have surged approximately 300% since 2020.
This comprehensive guide synthesizes the latest data (2022–2026) from SAMHSA, the CDC, ASPE/HHS, NSCH, NSDUH, the FDA, AAP, peer-reviewed journals, and industry reports to provide clinicians, researchers, pharmacists, policymakers, and parents with the most complete pediatric medication use statistics available. Every statistic links directly to its primary source.
Key Takeaways
- Nearly 30% of U.S. children aged 5–25 now have at least one chronic condition, up from ~26% two decades ago[1]
- The 8 fastest-rising pediatric chronic conditions (2011–2023): major depression, sleep apnea, eating disorders, anxiety, autism, obesity, lipid metabolism disorders, and developmental disorders[2]
- Stimulants remain the most commonly prescribed psychiatric medication for youth at 5.3% of 3–17-year-olds; SSRIs rose from 1.5% to 3.6% (2006–2023)[3]
- An estimated 7.1 million U.S. children (11.4%) have ever been diagnosed with ADHD; 53.6% of those with current ADHD receive medication
- Obesity medication prescriptions for adolescents increased ~300% from 2020 to 2023; 57.1% received semaglutide (Wegovy)[4]
- Pediatric asthma hospitalizations declined 44% from 2012 to 2019, and global pediatric asthma prevalence fell ~34% since 1990
- Only 31.4% of pediatric outpatient antibiotic prescriptions were optimal for both choice and duration[5]
- Youth-onset type 2 diabetes incidence rose 62% after the COVID-19 pandemic began and is projected to increase 700% by 2060
- 64% of new drugs and biologics lack pediatric prescribing information within 5 years of FDA approval; ~45% of outpatient pediatric prescriptions are off-label
- Kindergarten vaccination rates continued to decline in 2024–25, with exemptions hitting a record 3.6%[6]
What Are Pediatric Medicines and Why Do Trends Matter?
Pediatric medicines encompass all pharmacologic agents — prescription and over-the-counter — used in patients from birth through 17 years of age. Children are not simply “small adults”; they differ substantially in pharmacokinetics, pharmacodynamics, organ maturity, and susceptibility to adverse effects. Yet fewer than half of medications contain pediatric-specific prescribing information on their label, and 64% of new drugs and biologics lack pediatric prescribing information within 5 years of FDA approval.
Tracking medication use trends in children serves as a powerful epidemiologic proxy: when prescribing for a particular drug class rises, it typically reflects an increase in the underlying disease prevalence, expanded diagnostic criteria, shifting treatment guidelines, or changing clinical practice. This article examines the major therapeutic drug classes prescribed to children, what they reveal about pediatric disease trends, and where the gaps and opportunities lie.
Key medication categories covered:
- Stimulants and ADHD medications — the most commonly prescribed psychiatric class in children
- Antidepressants (SSRIs) — the fastest-rising psychiatric class in youth
- Antibiotics — the most frequently prescribed overall drug class in pediatric outpatient visits
- Asthma medications (bronchodilators, inhaled corticosteroids) — reflecting shifting respiratory disease trends
- Obesity and metabolic medications — an emerging and rapidly growing class
- Vaccines — the most widely administered pediatric pharmaceutical intervention
- Antipyretics/analgesics (acetaminophen, ibuprofen) — the most common OTC pediatric medications
Pediatric Chronic Disease: The Epidemiologic Context
Understanding medicine use in children requires first understanding the disease landscape. Nearly 1 in 3 young people in the U.S. now lives with a chronic condition, and this prevalence has increased by 15–20% over the past decade.
Fastest-Rising Chronic Conditions (2011–2023)
Data from both the National Survey of Children’s Health (NSCH) and the PEDSnet multi-institutional research network reveal the following conditions with the steepest increases:
| Condition | Trend (2011–2023) | Estimated U.S. Pediatric Prevalence (2025) |
|---|---|---|
| Anxiety | Highest level of increase [7] | Rising sharply |
| Major Depression | Among top risers [2] | Rising sharply |
| Autism Spectrum Disorder | Significant increase [7] | ~4.6 million [2] |
| Obesity | Significant increase [2] | ~14.1 million [2] |
| ADHD | Significant increase [7] | ~5.6 million diagnosed [2] |
| Eating Disorders | Among top 8 risers [2] | Rising |
| Sleep Apnea | Among top 8 risers [2] | Rising |
| Developmental Disorders | Significant increase [2] | Rising |
Notably, asthma prevalence significantly decreased during this period — one of the few pediatric conditions to show sustained improvement. This is directly reflected in declining asthma medication utilization and hospitalizations.[7]
Key Drivers
The rise in chronic conditions is largely driven by ADHD/ADD, autism, asthma improvements notwithstanding, prediabetes, and depression/anxiety. Youth who are subject to socioeconomic vulnerability — lower income, less education, public insurance, unemployment — are significantly more likely to live with a chronic condition.[1]
Stimulants and ADHD Medications
ADHD Prevalence
ADHD is the most common neurodevelopmental disorder in childhood. Current data show:
- 7.1 million U.S. children aged 3–17 (11.4%) have ever been diagnosed with ADHD — approximately 1 in 9 children
- 6.5 million (10.5%) had current ADHD in 2022
- This represents an increase of ~1 million more children diagnosed compared to 2016 (6.1 million)
- 58.1% had moderate or severe ADHD
- 77.9% had at least one co-occurring disorder
Stimulant Prescribing Trends
Stimulants remain the most commonly prescribed psychiatric medication class for children:[3]
| Year | Youth Stimulant Prevalence (Ages 3–17) | SSRI Prevalence | Antipsychotic Prevalence | Mood Stabilizer Prevalence |
|---|---|---|---|---|
| 2006 | ~5.0% | 1.5% | 1.3% | ~1.0% |
| 2011 | ~5.5% (peak) | ~2.0% | ~1.2% | ~0.9% |
| 2017 | ~5.0% | ~2.5% | ~1.1% | ~0.8% |
| 2023 | 5.3% | 3.6% | 1.1% | 0.8% |
Source: ASPE/HHS 2025 Data Point Report[3]
Key trends in stimulant prescribing:
- Stimulant use remained relatively stable among children after peaking around 2011, while it increased substantially in adults[3]
- 53.6% of children with current ADHD received ADHD medication in 2022[8]
- Among those prescribed ADHD medication, 60–67% received stimulants only, 13–15% received stimulant/nonstimulant combinations[9]
- Methylphenidate remains the most commonly prescribed stimulant among children[10]
- 90% of all dispensed medications for ADHD were stimulants; 10% were nonstimulants[11]
- In Canada/Ontario, overall new stimulant prescriptions increased 157.2% from 2015 to 2023, accelerating after 2020 (+28%/year vs. +7%/year pre-pandemic)
- The Adderall shortage (October 2022) shifted prescribing to alternatives but did not reduce overall stimulant dispensing rates[12]
Treatment Gap
Despite the high prevalence of ADHD, nearly one-third (30.1%) of children with current ADHD did not receive any ADHD-specific treatment — neither medication nor behavioral therapy. Only 44.4% had received behavioral treatment in the past year.[8]
Antidepressants and SSRIs in Children
The Fastest-Rising Pediatric Psychiatric Medication Class
SSRI prescribing for children represents the most notable trend in pediatric psychiatric medication over the past two decades:[3]
- SSRI use in youth aged 3–17 increased from 1.5% in 2006 to 3.6% in 2023 — a 140% increase[3]
- The acceleration was most pronounced in recent years, coinciding with rising anxiety and depression diagnoses
- Antidepressant prescriptions are increasing worldwide among children and adolescents, with SSRIs — mainly fluoxetine — predominantly prescribed[13]
- Only fluoxetine (Prozac) is FDA-approved for depression in children aged 8+; escitalopram (Lexapro) is approved for ages 12+[14]
What This Tells Us About Disease Trends
The surge in SSRI prescribing mirrors the dramatic rise in pediatric anxiety and depression:[7]
- Anxiety had the highest level of increase of any chronic condition in children from 2011 to 2023[7]
- Depression was among the top 8 fastest-rising conditions[2]
- Depression incidence in youth aged 5–22 increased approximately 60% from 2017 to 2021; anxiety incidence increased 31%[15]
- Nearly 1 in 5 adolescents (12–17) had moderate or severe anxiety symptoms in 2024[16]
Antipsychotics and Mood Stabilizers
In contrast to SSRIs, antipsychotic and mood stabilizer use among children has stayed the same or slightly decreased over time:[3]
- Antipsychotic prevalence in youth narrowly oscillated around 1.2% throughout the study period, declining from 1.3% in 2006 to 1.1% by 2023[3]
- Mood stabilizer prevalence declined slightly to 0.8% by 2023[3]
- These trends contrast with increased prescribing in adults, suggesting different clinical needs between populations[3]
Antibiotics: The Most Prescribed and Most Overused
Outpatient Antibiotic Use
Antibiotics remain the most frequently prescribed drug class in pediatric outpatient visits. However, overuse remains a major concern:
- In 2024, the overall U.S. outpatient antibiotic prescribing rate was 752 prescriptions per 1,000 population, reflecting a 1% decline from 2023[17]
- An estimated one-third of outpatient antibiotic prescriptions in children are unnecessary[18]
- Only 31.4% of pediatric outpatient antibiotic prescriptions were optimal for both antibiotic choice and duration of therapy[5]
- 39% of all pediatric antibiotics were prescribed for conditions (Tier 3 diagnoses) that almost never require antibiotics — this was “almost entirely unnecessary”[5]
- Children under 5 and patients with otitis media or acute respiratory infections are at the highest risk for unnecessary prescriptions[18]
Antibiotic Prescribing Patterns
| Finding | Data |
|---|---|
| Antibiotics optimal for choice AND duration | 31.4% [5] |
| Prescribed for conditions rarely needing antibiotics | 39.0% [5] |
| Prescribing rate in Tennessee vs. national average (2016) | 50% higher [5] |
| CDC estimate of unnecessary outpatient prescriptions | ≥50% [5] |
| UK: pediatric antibiotic exposure rate (March 2025) | 31.7% (down from 34.9% in March 2024) [19] |
Implications for Antimicrobial Resistance
Downstream outcomes of pediatric antibiotic overuse include antimicrobial resistance, adverse medication effects, and chronic conditions secondary to microbiome alterations, such as inflammatory bowel disease and asthma. Strengthened outpatient stewardship strategies targeting respiratory visits and young children are urgently needed.
Asthma Medications: A Declining Trend
Pediatric Asthma — A Rare Good-News Story
Unlike most pediatric chronic conditions, asthma prevalence and its associated medication use have been declining:
- ~4.9 million U.S. children currently have asthma[20]
- Asthma prevalence significantly decreased from 2011 to 2023, one of the few conditions to improve[7]
- Global pediatric asthma prevalence fell ~34% from 1990 to 2021, with the largest reduction among preschoolers (<5 years)[21]
- Pediatric asthma hospitalizations declined from 114,325 in 2012 to 64,525 in 2019 — a 44% reduction[22]
- Hospitalization rates decreased by approximately 0.83 per 10,000 children per year[22]
- Projected prevalence rate is expected to decline a further 39.5% by 2050[21]
Factors Behind the Decline
Several factors contribute to declining asthma medication use and hospitalizations:[22]
- Improved management of asthma exacerbations in emergency settings
- Better access to outpatient care and controller medications
- Improved provider and parent confidence in outpatient management
- Rising inpatient costs encouraging outpatient alternatives
Persistent Disparities
Despite overall improvement, racial disparities remain stark. Non-Hispanic Black children had asthma hospitalization rates 3–4 times higher than non-Hispanic White children (range 9.8–36.7 vs. 2.2–9.4 per 10,000 children).[22]
Childhood Obesity Epidemic
Childhood obesity continues to fuel an entirely new category of pediatric prescribing:
- 19.3% of U.S. children ages 2–19 are obese[23]
- An estimated 14.1 million total prevalent pediatric cases of obesity in the U.S. in 2025[2]
- Obesity was among the top 8 fastest-rising pediatric conditions from 2011 to 2023[2]
- Childhood obesity figures are expected to double by 2035 from 2020 levels globally[24]
Surge in Obesity Medication Prescriptions
The most dramatic recent shift in pediatric prescribing involves anti-obesity medications:[4]
- Obesity medication prescriptions for adolescents with obesity increased ~300% from 2020 to 2023[4]
- In 2023, among adolescents with obesity prescribed medication:
- 57.1% received semaglutide (Wegovy)
- 37.7% received phentermine or phentermine-topiramate
- 11.9% received liraglutide (Saxenda)[4]
- Adolescents with class 3 obesity were 12.78 times more likely to be prescribed obesity medications than those with class 1[4]
- The surge followed FDA’s expanded approval of two obesity medications to include adolescents and publication of the AAP clinical practice guideline in 2023[4]
Youth-Onset Type 2 Diabetes
The obesity epidemic is directly driving a parallel rise in youth-onset type 2 diabetes:
- Type 2 diabetes incidence in U.S. youth rose 62% after the COVID-19 pandemic began (from 14.8 to 24.7 per 100,000 person-years)[25]
- Rates have doubled since 2002–2003 (from 9 to 17.9 per 100,000 youth aged 10–19)[26]
- Prevalence is projected to increase 700% by 2060 if current trends continue
- An estimated 18% of U.S. youth aged 12–18 had HbA1c-based prediabetes (2005–2016 NHANES data)[27]
- Metformin remains the only widely used medication for type 2 diabetes in children aged 10+[23]
- Youth-onset T2DM is more aggressive than adult-onset, with earlier and more severe cardiovascular and renal complications[28]
Over-the-Counter Medications: Acetaminophen and Ibuprofen
Acetaminophen (paracetamol) and ibuprofen are the most commonly used OTC medications for managing fever and pain in children worldwide:[29]
- Acetaminophen use declined slightly from 68.8% in 2019 to 63.5% in 2024[29]
- Ibuprofen use grew by over 60% from 2020 to 2024, with reported adverse drug reactions also increasing[29]
- The proportion of pediatric ibuprofen purchased OTC rose from 28% in 2008 to 70% in 2015[29]
- Paracetamol (acetaminophen) was the most frequently prescribed medication in pediatric inpatient wards across a five-country study[30]
The increased accessibility of ibuprofen (no prescription required in many countries since 2009) has led to wider perception of safety and increased consumption, which warrants continued pharmacovigilance.[29]
Vaccines: Declining Coverage, Rising Concerns
Kindergarten Vaccination Rates
Childhood vaccination — the most widely administered pediatric pharmaceutical intervention — is experiencing concerning declines:
| Vaccine | 2019–20 Coverage | 2023–24 Coverage | 2024–25 Coverage |
|---|---|---|---|
| MMR | 95.2% | 92.7% | 92.5% [6] |
| Polio (IPV) | 95.0% | 92.7% | 92.5% [6] |
| Varicella (2 doses) | — | 92.3% | 92.1% [6] |
Key concerns:
- Vaccination coverage declined for all reported vaccines in kindergartners during the 2024–25 school year[6]
- Coverage declined from the previous year in more than half of states[6]
- Vaccine exemptions hit a record 3.6% of kindergartners (up from 2.5% in 2020–21), with ~138,000 children exempted[6]
- 17 states reported exemption rates exceeding 5%; Idaho had the highest at 15.4%[6]
- As of July 2025, there were 1,333 confirmed measles cases in 39 states — more than 4 times the 2024 total of 285 — with 29% in children under 5[31]
- 92% of all 2025 measles cases were in individuals classified as “unvaccinated or unknown”[31]
Off-Label Prescribing in Children
Off-label medication use remains pervasive in pediatrics due to the limited number of drugs formally studied and approved for children:
- ~45% of outpatient pediatric prescriptions are off-label[32]
- Over 80% of neonatal prescriptions are off-label[33]
- 64% of new drugs and biologics lack pediatric prescribing information within 5 years of FDA approval[33]
- 40% of ordered medications for hospitalized pediatric patients, and >50% for neonates, remain off-label by indication[33]
- Despite progress through the Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA), many older, generic drugs still lack pediatric data[33]
The 2025 KIDs List (Key Potentially Inappropriate Drugs in Pediatrics) identified high-risk medications requiring special caution, including tetracyclines (tooth discoloration, avoid <8 years), tricyclic antidepressants (cardiac risk, avoid ≤18 years), and valproic acid (fatal hepatotoxicity risk, avoid <2 years).[33]
What Medication Trends Tell Us About Pediatric Disease
Conditions Rising (Medication Use Increasing)
| Disease Trend | Medication Signal | Interpretation |
|---|---|---|
| Anxiety & Depression ↑ | SSRI prescriptions +140% (2006–2023) [3] | Reflects genuine increase in pediatric mental health disorders |
| ADHD ↑ | 7.1 million diagnosed (up from 6.1M in 2016) [34] | Expanded recognition + possible over-diagnosis |
| Childhood Obesity ↑ | Obesity Rx +300% in adolescents (2020–2023) [4] | New pharmacotherapy era post-AAP/FDA changes |
| Youth-Onset T2DM ↑ | Metformin + insulin use growing [24] | Downstream consequence of obesity epidemic |
| Food Allergies ↑ | Epinephrine autoinjector use rising [35] | Growing allergic disease burden |
Conditions Declining (Medication Use Stable or Declining)
| Disease Trend | Medication Signal | Interpretation |
|---|---|---|
| Asthma ↓ | Hospitalizations -44% (2012–2019) [22] | Better outpatient management, controller medications |
| Vaccine-preventable diseases (until recently) | Vaccination rates declining [6] | Risk of resurgence (measles already surging) |
| Antibiotic need ↓ | Prescribing rates slowly declining (-1% in 2024) [17] | Stewardship efforts working, but 39% still unnecessary [5] |
Key Insight
The data reveal a fundamental epidemiologic transition in pediatric medicine: the burden is shifting from acute infectious disease and respiratory conditions (which are declining) toward chronic neurodevelopmental, behavioral, and metabolic conditions (which are rising). This shift demands corresponding changes in healthcare delivery, workforce training, medication research, and public health investment.
The Pediatric Medication Safety Challenge
Adverse Drug Reactions
Children face unique medication safety challenges:
- Substantial limitations exist in evaluating medications for pediatric use before market entry
- Safety concerns are often identified after FDA approval
- The high frequency of off-label use means many prescribing decisions rely on case reports, observational experience, and historical practice rather than rigorous pediatric trials[33]
- Approximately 20% of pediatric outpatient visits result in one or more off-label prescriptions[33]
- Pediatric ibuprofen ADR reports increased alongside the 60% growth in pediatric ibuprofen use from 2020 to 2024[29]
Opioid Exposure in Young Children
Opioid exposures among young children reported to U.S. Poison Centers showed mixed trends from 2016 to 2023:[36]
- Total reported exposures decreased by 57.5% over the study period
- However, deaths and major effects increased 300% (absolute increase)
- Buprenorphine was the most frequently involved opioid (23.4% of exposures) — reflecting the wider use of medications for opioid use disorder in households with children
- Heroin/fentanyl/synthetic opioid reports increased 512% and were associated with 20x the risk of severe effects[36]
The Global Perspective
WHO Essential Medicines List for Children
The WHO updated its Essential Medicines List for Children (EMLc) to the 10th edition in September 2025, providing guidance to countries on priority medications for pediatric populations.[37]
International Prescribing Variations
Prescribing patterns vary significantly across countries, reflecting different treatment strategies, formulary decisions, and disease profiles:[30]
- Paracetamol (acetaminophen) was the most frequently prescribed drug in pediatric wards across Australia, Germany, the UK, Hong Kong, and Malaysia[30]
- Metamizole was used only in Germany; morphine was prescribed mainly in the UK[30]
- The U.S. has the highest number of approved ADHD medicines and formulations (29 medicine forms for 10 approved medicines) across five studied countries[38]
- ADHD medication use among children aged 6–17 increased globally from 15.9 to 30.3 per 1,000 between 2006 and 2022[10]
Looking Ahead: 2026 and Beyond
Emerging Trends to Watch
- GLP-1 receptor agonists in pediatric obesity: Following the ~300% increase in adolescent obesity medication prescriptions, semaglutide and liraglutide are poised to become standard care for severe pediatric obesity, with potential downstream effects on type 2 diabetes prevention[4]
- Digital therapeutics for ADHD and mental health: FDA-cleared digital therapeutics (like prescription video game-based interventions) represent a new medication-adjacent category
- Expanded pediatric indications: The BPCA and PREA continue to push for pediatric-specific data, but the 64% gap in pediatric labeling within 5 years of approval remains a critical challenge[33]
- Antibiotic stewardship scaling: CDC is updating Outpatient Core Elements in 2026 to focus on health system leadership roles in pediatric stewardship[17]
- Vaccination crisis: With exemption rates at record highs and measles cases surging 4x, pediatric vaccine coverage may become the most urgent pharmacotherapy challenge of 2026
- AI and real-world data in pediatric drug safety: Advancing use of electronic health records, claims data, and AI to identify safety signals and improve medication prescribing for children[32]
Post Views: 32
References
- Pediatric chronic disease prevalence has risen to nearly 30% in the last 20 years, study suggests. https://medicalxpress.com/news/2025-03-pediatric-chronic-disease-prevalence-risen.html Accessed March 5, 2026
- Chronic conditions increase in US children over last decade. https://www.clinicaltrialsarena.com/analyst-comment/chronic-conditions-increase-us-children-last-decade/ Accessed March 5, 2026
- 403 Forbidden. https://aspe.hhs.gov/sites/default/files/documents/1ef68c455fa5aa5932acf481b0954ddf/DataPoint_PsychRxPrev_BHDAP_20250409%20July%2031%202025.pdf Accessed March 5, 2026
- Prescriptions for Obesity Medications Among Adolescents Aged 12–17 Years with Obesity — United States, 2018–2023 . https://www.cdc.gov/mmwr/volumes/74/wr/mm7420a1.htm Accessed March 5, 2026
- Just a moment…. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824352 Accessed March 5, 2026
- US childhood vaccination rates continue to fall, CDC data show. https://www.cidrap.umn.edu/childhood-vaccines/us-childhood-vaccination-rates-continue-fall-cdc-data-show Accessed March 5, 2026
- Trends in US Children’s Mortality, Chronic Conditions, Obesity, Functional Status, and Symptoms. https://pmc.ncbi.nlm.nih.gov/articles/PMC12235530/ Accessed March 5, 2026
- Just a moment…. https://www.tandfonline.com/doi/full/10.1080/15374416.2024.2335625 Accessed March 5, 2026
- Just a moment…. https://journals.lww.com/10.1097/DBP.0000000000001296 Accessed March 5, 2026
- Global Trends in ADHD Medication Use: Multiple Contexts and Rising Concerns—A Narrative Review. https://pmc.ncbi.nlm.nih.gov/articles/PMC12565614/ Accessed March 5, 2026
- https://www.deadiversion.usdoj.gov/pubs/docs/IQVIA-Report-on-Stimulant-Trends-2024.pdf. https://www.deadiversion.usdoj.gov/pubs/docs/IQVIA-Report-on-Stimulant-Trends-2024.pdf Accessed March 5, 2026
- Adderall Shortage Drives Shift to Alternative ADHD Medications in Children. https://www.pharmexec.com/view/adderall-shortage-drives-shift-alternative-adhd-medications-children Accessed March 5, 2026
- Increased Antidepressant Prescriptions for Children and Adolescents with Major Depressive Disorder in Japan Based on a Claims Database. https://pmc.ncbi.nlm.nih.gov/articles/PMC12572637/ Accessed March 5, 2026
- Mental Health: Depression. https://www.childrensmercy.org/health-care-providers/refer-or-manage-a-patient/connect-with-childrens-mercy/newsletter-the-link/the-link-2025/the-link—january-2025/mental-health-depression/ Accessed March 5, 2026
- Just a moment…. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824286 Accessed March 5, 2026
- SAMHSA. https://www.facebook.com/samhsa/posts/-nsduhs-first-data-on-anxiety-symptoms-in-2024-nearly-1-in-5-adolescents-12-17-h/1287181489425303/ Accessed March 5, 2026
- Antibiotic Use and Stewardship in the United States, 2025 Update: Progress and Opportunities | Antibiotic Prescribing and Use. https://www.cdc.gov/antibiotic-use/hcp/data-research/stewardship-report.html Accessed March 5, 2026
- Patterns of Antibiotic Prescribing for Pediatric Outpatient Visits in the United States: Findings From the National Ambulatory Medical Care Survey …. https://pmc.ncbi.nlm.nih.gov/articles/PMC12756683/ Accessed March 5, 2026
- Dialling back antibiotic prescribing in children. https://pharmaceutical-journal.com/article/feature/dialling-back-antibiotic-prescribing-in-children Accessed March 5, 2026
- Asthma in Children. https://aafa.org/asthma/living-with-asthma/asthma-in-children/ Accessed March 5, 2026
- Global burden of asthma among children and adolescents with projections to 2050: a comprehensive review and forecasted modeling study. https://pmc.ncbi.nlm.nih.gov/articles/PMC12062390/ Accessed March 5, 2026
- Trends in US Pediatric Asthma Hospitalizations, by Race and Ethnicity, 2012–2020. https://www.cdc.gov/pcd/issues/2024/24_0049.htm Accessed March 5, 2026
- Childhood obesity statistics 2025. https://www.singlecare.com/blog/news/childhood-obesity-statistics/ Accessed March 5, 2026
- Rising tide: The global surge of type 2 diabetes in children and adolescents demands action now. https://pmc.ncbi.nlm.nih.gov/articles/PMC11099374/ Accessed March 5, 2026
- Type 2 diabetes rates in US youth rose 62% after COVID pandemic began, study suggests. https://www.cidrap.umn.edu/covid-19/type-2-diabetes-rates-us-youth-rose-62-after-covid-pandemic-began-study-suggests Accessed March 5, 2026
- Understanding the sudden rise of type 2 diabetes in children. https://jheor.org/post/2623-understanding-the-sudden-rise-of-type-2-diabetes-in-children Accessed March 5, 2026
- Just a moment…. https://diabetesjournals.org/care/article/48/7/1136/158193/Youth-Onset-Type-2-Diabetes-What-We-ve-Learned Accessed March 5, 2026
- Youth-onset type 2 diabetes mellitus: an urgent challenge. https://pmc.ncbi.nlm.nih.gov/articles/PMC10182876/ Accessed March 5, 2026
- Adverse reactions to acetaminophen and ibuprofen in pediatric patients: a narrative review | Italian Journal of Pediatrics. https://ijponline.biomedcentral.com/articles/10.1186/s13052-025-02135-z Accessed March 5, 2026
- Drug Utilisation Patterns in Children Admitted to a Paediatric General Medical Ward in Five Countries. https://pmc.ncbi.nlm.nih.gov/articles/PMC4674526/ Accessed March 5, 2026
- CDC data finds kindergarten vaccination rates declined during 2024-25 school year. https://www.aha.org/news/headline/2025-08-04-cdc-data-finds-kindergarten-vaccination-rates-declined-during-2024-25-school-year Accessed March 5, 2026
- Advancing pediatric medication safety using real-world data: Current problems and potential solutions. https://pmc.ncbi.nlm.nih.gov/articles/PMC10460821/ Accessed March 5, 2026
- Pediatric Pharmacy Association 2025 KIDs List of Key Potentially Inappropriate Drugs in Pediatrics. https://pmc.ncbi.nlm.nih.gov/articles/PMC12351480/ Accessed March 5, 2026
- Data and Statistics on ADHD | Attention-Deficit / Hyperactivity Disorder (ADHD). https://www.cdc.gov/adhd/data/index.html Accessed March 5, 2026
- Food Allergy Anaphylaxis in Infants and Toddlers. https://aafa.org/asthma-allergy-research/our-research/food-allergy-anaphylaxis-in-infants/ Accessed March 5, 2026
- Just a moment…. https://www.tandfonline.com/doi/full/10.1080/15563650.2024.2401598 Accessed March 5, 2026
- WHO Model Lists of Essential Medicines. https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists Accessed March 5, 2026
- Investigating Variations in Medicine Approvals for Attention-Deficit/Hyperactivity Disorder: A Cross-Country Document Analysis Comparing Drug Labeling. https://pmc.ncbi.nlm.nih.gov/articles/PMC11328451/ Accessed March 5, 2026
